Pubblicazioni

2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma

2023 - ANNALS OF ONCOLOGY

Occhipinti, M.; Brambilla, M.; Ambrosini, P.; Pannone, A.; Zanella, C.; Leone, A. G.; Leporati, R.; Fotia, G.; Di Mauro, R.; Ianza, A.; Manglaviti, S.; Beninato, T.; Mazzeo, L.; Proto, C.; Prelaj, A.; Percio, S.; De Braud, F. G. M.; Lo Russo, G.; Generali, D.; Ganzinelli, M.

1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib

2023 - ANNALS OF ONCOLOGY

Brambilla, M.; Lorenzini, D.; Occhipinti, M.; Manglaviti, S.; Beninato, T.; Mazzeo, L.; Agnelli, L.; Leporati, R.; Zanella, C.; Leone, A. G.; Fotia, G.; Prelaj, A.; Lo Russo, G.; Grande, I.; Tamborini, E.; Perrone, F.; Ganzinelli, M.; Pruneri, G.; De Braud, F. G. M.; Proto, C.

178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients

2023 - ANNALS OF ONCOLOGY

Provenzano, L.; Favali, M.; Mazzeo, L.; Spagnoletti, A.; Giani, C.; Calareso, G.; Ruggirello, M.; Greco, F. G.; Vigorito, R.; Occhipinti, M.; Brambilla, M.; Manglaviti, S.; Proto, C.; Lo Russo, G.; TrovÃ², F.; De Braud, F. G. M.; Ganzinelli, M.; Pedrocchi, A.; Miskovic, V.; Prelaj, A.

P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study

2023 - ANNALS OF ONCOLOGY

Signorelli, C.; Calegari, M.; Basso, M.; Anghelone, A.; Lucchetti, J.; Minelli, A.; Angotti, L.; Zurlo, I.; Schirripa, M.; Chilelli, M.; Morelli, C.; DellâAquila, E.; Cosimati, A.; Gemma, D.; Ribelli, M.; Corsi, D.; Arrivi, G.; Zoratto, F.; Morandi, M.; Santamaria, F.; Saltarelli, R.; Ruggeri, E.

P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis

2023 - ANNALS OF ONCOLOGY

Trovato, G.; Valente, G.; Calegari, M.; DellâAquila, E.; Anghelone, A.; Lucchetti, J.; Schietroma, F.; Zurlo, I.; Signorelli, C.; Morelli, C.; Zoratto, F.; Caira, G.; Spring, A.; Saltarelli, R.; Cosimati, A.; Schirripa, M.; Santamaria, F.; Angotti, L.; Salvatore, L.; Pozzo, C.; Basso, M.; Tortora, G.

P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis

2023 - ANNALS OF ONCOLOGY

Caira, G.; Calegari, M.; Anghelone, A.; Lucchetti, J.; DellâAquila, E.; Signorelli, C.; Spring, A.; Saltarelli, R.; Cosimati, A.; Zurlo, I.; Angotti, L.; Schietroma, F.; Pozzo, C.; Chiofalo, L.; Santamaria, F.; Morelli, C.; Zoratto, F.; Schirripa, M.; Salvatore, L.; Basso, M.; Tortora, G.

127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma

2022 - ANNALS OF ONCOLOGY

Marinelli, D.; Pisegna, S.; Chiavassa, A.; Bengala, E.; Capasso, C.; Sabatini, A.; Ciurluini, F.; Artemi, A.; Torchia, A.; Gallina, F. T.; Botticelli, A.; Gazzaniga, P.; Cortesi, E.; Gelibter, A. J.

56P The prognostic role of {KRAS} mutations in patients with early-stage lung adenocarcinoma after robotic lobectomy and systematic lymphadenectomy

2022 - ANNALS OF ONCOLOGY

Gallina, F. T.; Marinelli, D.; Forcella, D.; Taj(`(e)), R.; Ceddia, S.; Fusco, F.; Melis, E.; Buglioni, S.; Visca, P.; Cappuzzo, F.; Facciolo, F.

Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients

2022 - ANNALS OF ONCOLOGY

Prelaj, A; Bottiglieri, A; Provenzano, L; Spagnoletti, A; Mazzeo, L; Miskovic, V; Ganzinelli, M; Lo Russo, G; Ferrara, R; Proto, C; De Toma, A; Brambilla, M; Occhipinti, M; Manglaviti, S; Beninato, T; Rametta, A; Garassino, Mc; De Braud, Fgm; Trovo, F; Pedrocchi, A

KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC

2022 - ANNALS OF ONCOLOGY

Bottiglieri, A; Provenzano, L; Spagnoletti, A; Mazzeo, L; Ganzinelli, M; Lo Russo, G; Ferrara, R; Proto, C; De Toma, A; Brambilla, M; Occhipinti, M; Manglaviti, S; Beninato, T; Garassino, Mc; Filosa, J; Di Guida, G; De Braud, Fgm; Viscardi, G; Della Corte, Cm; Prelaj, A

Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations

2022 - ANNALS OF ONCOLOGY

Ferrara, R; Lo Russo, G; Ciniselli, Cm; Gregorio, S; Calareso, G; Bassani, B; Proto, C; Prelaj, A; De Toma, A; Occhipinti, M; Brambilla, M; Manglaviti, S; Mazzeo, L; Beninato, T; Ganzinelli, M; De Braud, Fgm; Garassino, Mc; Colombo, Mp; Verderio, P; Sangaletti, S

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations

2022 - ANNALS OF ONCOLOGY

Beninato, T; Brambilla, M; Pircher, Cc; Mazzeo, L; Rametta, A; Manglaviti, S; De Toma, A; Galli, G; Prelaj, A; Ferrara, R; Proto, C; Lo Russo, G; Ganzinelli, M; Di Mauro, R; Di Nucci, A; Garassino, Mc; Marchetti, P; De Braud, Fgm; Occhipinti, M

DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients

2022 - ANNALS OF ONCOLOGY

Filetti, M; Occhipinti, M; Cirillo, A; Scirocchi, F; Ugolini, A; Petti, M; Giusti, R; Lombardi, P; Botticelli, A; Lo Russo, G; De Braud, Fgm; Marchetti, P; Nuti, M; Ferretti, E; Rughetti, A; Farina, L

133P ARID1A-mutated cancers: New prospectives for treatment of a subgroup of gynecological cancer

2022 - ANNALS OF ONCOLOGY

Falcone, R.; Filetti, M.; Lombardi, P.; Altamura, V.; Scambia, G.; Daniele, G.

1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis

2022 - ANNALS OF ONCOLOGY

Filetti, M.; Lombardi, P.; Falcone, R.; Giannarelli, D.; CarcagnÃ¬, A.; Giusti, R.; Scambia, G.; Daniele, G.

398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment

2022 - ANNALS OF ONCOLOGY

Signorelli, C.; Schirripa, M.; Chilelli, M. G.; Calegari, M. A.; Basso, M.; Anghelone, A.; Lucchetti, J.; Minelli, A.; Angotti, L.; Morelli, C.; Dell'Aquila, E.; Cosimati, A.; Gemma, D.; Ribelli, M.; Corsi, D. C.; Arrivi, G.; Zoratto, F.; Morandi, M. G.; Santamaria, F.; Saltarelli, R.; Ruggeri, E. M.

1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy

2021 - ANNALS OF ONCOLOGY

Zattarin, E.; Manglaviti, S.; Galli, E.; Apollonio, G.; Beninato, T.; Mazzeo, L.; Massa, G.; Bottiglieri, A.; Ganzinelli, M.; Proto, C.; Ferrara, R.; Prelaj, A.; Galli, G.; De Toma, A.; Brambilla, M.; Occhipinti, M.; Garassino, M. C. C.; De Braud, F. G. M.; Lo Russo, G.

1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation

2021 - ANNALS OF ONCOLOGY

Prelaj, A.; Bottiglieri, A.; Galli, E.; Lo Russo, G.; Ferrara, R.; Galli, G.; De Toma, A.; Brambilla, M.; Occhipinti, M.; Manglaviti, S.; Beninato, T.; Zattarin, E.; Apollonio, G.; Ganzinelli, M.; Gallucci, R.; Di Mauro, R. M.; de Braud, F.; Torri, V.; Garassino, M. C. C.; Proto, C.

3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors

2021 - ANNALS OF ONCOLOGY

Marinelli, D.; Pisegna, S.; Giammaruco, M.; Chesi, P.; Mammone, G.; Ceddia, S.; Gazzaniga, P.; Cortesi, E.; Gelibter, A. J.

10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status

2021 - ANNALS OF ONCOLOGY

Cortellini, A.; Filetti, M.; Citarella, F.; Giusti, R.; Russano, M.; Grossi, F.; Gelibter, A. J.; Pecci, F.; De Tursi, M.; Macerelli, M.; Nigro, O.; Ferrara, M. G.; Buti, S.; Mazzoni, F.; Cantini, L.; Migliorino, M. R.; Addeo, A.; Adamo, V.; Russo, A.; Pinato, D. J.

966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy

2021 - ANNALS OF ONCOLOGY

Cortellini, A.; Mallardo, D.; Cleary, S.; Bersanelli, M.; Santini, D.; Tucci, M. G.; Russo, A.; Rastelli, F.; Filetti, M.; Gelibter, A. J.; Marconcini, R.; Chiari, R.; Grossi, F.; De Tursi, M.; Queirolo, P.; Zoratto, F.; Tanda, E. T.; Porzio, G.; Ascierto, P. A.; Pinato, D. J.

1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program

2020 - ANNALS OF ONCOLOGY

Prelaj, A.; Bottiglieri, A.; Proto, C.; Lo Russo, G.; Signorelli, D.; Ferrara, R.; Galli, G.; De Toma, A.; Viscardi, G.; Brambilla, M.; Lobefaro, R.; Manglaviti, S.; Occhipinti, M.; Labianca, A.; Gallucci, R.; Molino, G.; Zilembo, N.; Greco, F. G.; Torri, V.; Garassino, M. C.

IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+T-cells

2020 - ANNALS OF ONCOLOGY

Ugolini, A; Zizzari, Ig; Ceccarelli, F; Botticelli, A; Colasanti, T; Strigari, L; Rughetti, A; Rahimi, H; Conti, F; Valesini, G; Marchetti, P; Nuti, M

The evolving impact of genomic biomarker landscape in stage II colorectal cancer (CRC).

2020 - ANNALS OF ONCOLOGY

Arrivi, G.; Marchetti, P.; Pilozzi, E.; Montori, A.; Balducci, G.; Mercantini, P.; Laghi, A.; IerinoÌ, D.; Panebianco, M.; Mazzuca, F.; Roberto, M.

A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

2019 - ANNALS OF ONCOLOGY

Parisi, A.; Cortellini, A.; Roberto, M.; Venditti, O.; Santini, D.; DellâAquila, E.; Stellato, M.; Marchetti, P.; Occhipinti, M.; Zoratto, F.; Mazzuca, F.; Tinari, N.; De Tursi, M.; Iezzi, L.; Natoli, C.; Ratti, M.; Pizzo, C.; Ghidini, M.; Ficorella, C.; Cannita, K.